- Home
- PPSI vs BOLD Comparison
PPSI vs BOLD Comparison
Compare PPSI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPSI
- BOLD
- Stock Information
- Founded
- PPSI 2008
- BOLD 2018
- Country
- PPSI United States
- BOLD United States
- Employees
- PPSI N/A
- BOLD N/A
- Industry
- PPSI Electrical Products
- BOLD
- Sector
- PPSI Industrials
- BOLD
- Exchange
- PPSI Nasdaq
- BOLD Nasdaq
- Market Cap
- PPSI 30.0M
- BOLD 24.4M
- IPO Year
- PPSI N/A
- BOLD 2024
- Fundamental
- Price
- PPSI $3.14
- BOLD $1.21
- Analyst Decision
- PPSI Strong Buy
- BOLD Buy
- Analyst Count
- PPSI 1
- BOLD 3
- Target Price
- PPSI $12.00
- BOLD $4.00
- AVG Volume (30 Days)
- PPSI 56.5K
- BOLD 280.0K
- Earning Date
- PPSI 09-09-2025
- BOLD 08-11-2025
- Dividend Yield
- PPSI 47.77%
- BOLD N/A
- EPS Growth
- PPSI N/A
- BOLD N/A
- EPS
- PPSI 2.84
- BOLD N/A
- Revenue
- PPSI $26,304,000.00
- BOLD N/A
- Revenue This Year
- PPSI $24.01
- BOLD N/A
- Revenue Next Year
- PPSI $19.25
- BOLD N/A
- P/E Ratio
- PPSI $1.09
- BOLD N/A
- Revenue Growth
- PPSI 439.46
- BOLD N/A
- 52 Week Low
- PPSI $2.25
- BOLD $1.00
- 52 Week High
- PPSI $7.00
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- PPSI 74.55
- BOLD N/A
- Support Level
- PPSI $2.65
- BOLD N/A
- Resistance Level
- PPSI $2.82
- BOLD N/A
- Average True Range (ATR)
- PPSI 0.12
- BOLD 0.00
- MACD
- PPSI 0.06
- BOLD 0.00
- Stochastic Oscillator
- PPSI 87.20
- BOLD 0.00
About PPSI Pioneer Power Solutions Inc.
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.